These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4791053)

  • 41. Normal erythrocyte uroporphyrinogen I synthase in a kindred with acute intermittent porphyria.
    Mustajoki P
    Ann Intern Med; 1981 Aug; 95(2):162-6. PubMed ID: 7258864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
    Marsden JT; Rees DC
    J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative aspects of porphyria in man and animals.
    Levin EY
    Ann N Y Acad Sci; 1974 Nov; 241(0):347-59. PubMed ID: 4530664
    [No Abstract]   [Full Text] [Related]  

  • 44. Porphyrins in liver and urine in acute intermittent and chronic hepatic porphyrias.
    Doss M; Meinhof W; Look D; Henning H; Nawrocki P; Dölle W; Strohmeyer G; Filippini L
    S Afr Med J; 1971 Sep; ():50-6. PubMed ID: 5150295
    [No Abstract]   [Full Text] [Related]  

  • 45. The incorporation of [4-14C] delta-aminolaevulic acid into urinary porphyrins in symptomatic porphyria.
    Goldswain P; Dowdle E; Spong N; Eales L
    Clin Sci; 1970 Aug; 39(2):159-68. PubMed ID: 5473578
    [No Abstract]   [Full Text] [Related]  

  • 46. Chester porphyria: biochemical studies of a new form of acute porphyria.
    McColl KE; Thompson GG; Moore MR; Goldberg A; Church SE; Qadiri MR; Youngs GR
    Lancet; 1985 Oct; 2(8459):796-9. PubMed ID: 2864531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation.
    Doss M; von Tiepermann R; Schneider J; Schmid H
    Klin Wochenschr; 1979 Oct; 57(20):1123-7. PubMed ID: 513604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS.
    TAYLOR JD; PAZDER LH; MARKLE V
    Can Med Assoc J; 1965 Jun; 92(26):1342-4. PubMed ID: 14312444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pathophysiology and diagnosis of acute intermittent porphyria].
    Wichmann T; Freye HA
    Z Gesamte Inn Med; 1977 Jun; 32(12):289-92. PubMed ID: 910533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic delta-aminolaevulinic acid synthetase in an attack of hereditary coproporphyria and during remission.
    McIntyre N; Pearson AJ; Allan DJ; Craske S; West GM; Moore MR; Beattie AD; Paxton J; Goldberg A
    Lancet; 1971 Mar; 1(7699):560-4. PubMed ID: 4100900
    [No Abstract]   [Full Text] [Related]  

  • 51. 17-Oxosteroid control of porphyrin biosynthesis.
    Moore MR; Paxton JW; Beattie AD; Goldberg A
    Enzyme; 1973; 16(1):314-25. PubMed ID: 4791050
    [No Abstract]   [Full Text] [Related]  

  • 52. [Disorders of porphyrin metabolism].
    Van de Velde R
    Fortschr Med; 1973 Sep; 91(26):1025-7. PubMed ID: 4742016
    [No Abstract]   [Full Text] [Related]  

  • 53. Acute hepatic porphyria syndrome with porphobilinogen synthase defect.
    Doss M; von Tiepermann R; Schneider J
    Int J Biochem; 1980; 12(5-6):823-6. PubMed ID: 7450139
    [No Abstract]   [Full Text] [Related]  

  • 54. Symptomatic porphyria I. The effects of lead on the synthesis of porphyrin and haem.
    Dowdle EB; Wilson E; Burger P
    S Afr Med J; 1971 Sep; ():38-45. PubMed ID: 5150293
    [No Abstract]   [Full Text] [Related]  

  • 55. Excretion of porphyrins and porphyrin precursors during neuromuscular paralysis produced by dithiobiuret.
    Atchison WD; Peterson RE
    Exp Neurol; 1984 Jul; 85(1):63-8. PubMed ID: 6428932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 17-Oxosteroid conjugates in plasma and urine of patients with acute intermittent porphyria.
    Paxton JW; Moore MR; Deattie AD; Goldberg A
    Clin Sci Mol Med; 1974 Feb; 46(2):207-22. PubMed ID: 4817273
    [No Abstract]   [Full Text] [Related]  

  • 57. The porphyrias [corrected]: characteristics and laboratory tests.
    Ellefson RD; Ford RE
    Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 2):S119-25. PubMed ID: 8921566
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycine loading test in acute intermittent porphyria patients and their relatives.
    Loriaux DL; Deleña S; Brown H
    Metabolism; 1969 Oct; 18(10):860-6. PubMed ID: 5823743
    [No Abstract]   [Full Text] [Related]  

  • 59. Excretion of porphobilinogen and 5-aminolaevulinic acid in acute porphyria.
    ACKNER B; COOPER JE; GRAY CH; KELLY M; NICHOLSON DC
    Lancet; 1961 Jun; 1(7189):1256-60. PubMed ID: 13681256
    [No Abstract]   [Full Text] [Related]  

  • 60. Biochemical basis and regulatory mechanisms of porphyrin synthesis.
    Neuberger A
    Proc R Soc Med; 1968 Feb; 61(2):191-3. PubMed ID: 5637834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.